News from janssen r A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 25, 2014, 08:25 ET

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired...

Aug 25, 2014, 08:00 ET

Janssen Diagnostics Expands Research Portfolio to Include Next-Generation Sequencing

 Janssen Diagnostics, LLC today announced the addition of next-generation sequencing (NGS) to the portfolio of services it provides...

Aug 25, 2014, 08:00 ET

Data on XARELTO® at ESC Congress 2014 Hot Line Session Premieres First Prospective Study of a Factor Xa Inhibitor in Elective Cardioversion

 Janssen Research & Development, LLC (Janssen) announced today that results from the Phase 3b exploratory X-VeRT study, investigating the...

Aug 20, 2014, 13:00 ET

SANAFOR™ Antimicrobial Technology For Plastics, From Janssen PMP, Receives U.S. EPA Registration

Janssen PMP has announced that SANAFOR™ PO-5 is now registered by the U.S. Environmental Protection Agency (EPA) as an antimicrobial...

Aug 11, 2014, 18:18 ET
Aug 08, 2014, 19:15 ET
http://www.multivu.com/players/English/7288451-janssen-pharmaceuticals-fda-approved-invokamet-type-2-diabetes/gallery/image/2245cacc-b245-46fe-b426-f788a88626a7.HR.jpg

U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

 Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKAMET™, a fixed-dose therapy...

Aug 05, 2014, 09:00 ET

Janssen Launches Online Healthy Minds Video Series

Janssen Research & Development, LLC, today launched the first in a series of online videos addressing key mental health topics and treatments...

Jul 28, 2014, 13:24 ET
IMBRUVICA(R) (ibrutinib) 140mg capsules. (PRNewsFoto/Janssen Biotech, Inc.)

IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p

The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for...

Jul 27, 2014, 16:28 ET

Janssen recibe la opinión positiva del CHMP sobre IMBRUVICA™

- Janssen recibe la opinión positiva del CHMP: se recomienda IMBRUVICA™ para su uso en el tratamiento de dos formas de cáncer...

Jul 27, 2014, 08:51 ET

Janssen reçoit un avis positif du CHMP recommandant l'utilisation d'IMBRUVICA™ dans le traitement de deux formes de cancer du sang

Janssen-Cilag International NV (Janssen) a annoncé aujourd'hui que le Comité des médicaments à usage humain (CHMP) de l'Agence...

Jul 27, 2014, 07:55 ET

Janssen erhält positive Meinungsäußerung des CHMP mit der Empfehlung von IMBRUVICA™ zum Einsatz bei der Behandlung von zwei Formen von Blutkrebs

Janssen-Cilag International NV (Janssen) gab heute bekannt, dass das Komitee für Medizinprodukte zur Anwendung am Menschen (Committee for...

Jul 25, 2014, 19:19 ET
http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg

El virus de la hepatitis C es la principal causa de los trasplantes de hígado en el mundo

 La División de Química, Alimentos y Medicamentos del Ministerio de Salud de Trinidad y Tobago aprobó la introducción de...

Jul 25, 2014, 11:16 ET
http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg

The Hepatitis C virus is the main cause of liver transplant in the world

 The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the...

Jul 14, 2014, 08:00 ET

Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed Time to Relapse Compared to Daily Oral Schizophrenia Therapies

 Janssen Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug...

Jun 24, 2014, 06:58 ET

Fighting for Their Lives: Economist Intelligence Unit Report Finds Patient Groups Lead Global Efforts to Address Hepatitis C

New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C...

Jun 18, 2014, 08:30 ET

Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A

Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for...

Jun 18, 2014, 07:59 ET

The Satisfaction Project challenges Canadians with psoriasis and psoriatic arthritis to take control and live better

~Expert panel shares tips, encouraging patients to take a 360° approach to managing their disease and to not give up until they're...

Jun 16, 2014, 17:00 ET

New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose in Older Patients with Type 2 Diabetes Inadequately Controlled on Other Therapies

 Janssen Research & Development, LLC (Janssen) today announced new results from a 104-week Phase 3 clinical study evaluating the long-term...

Jun 12, 2014, 06:00 ET

Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and...

Jun 10, 2014, 08:56 ET

Janssen to Present Latest Data for Type 2 Diabetes Treatment INVOKANA® (canagliflozin) at American Diabetes Association 74th Scientific Sessions®

 Janssen Research & Development, LLC (Janssen) announced today that 15 presentations on INVOKANA® (canagliflozin) will be made at the...